Navigation Links
Siemens Provides Breast Care Solutions - For Women. For Health. For Life.
Date:11/30/2008

of advanced imaging, laboratory diagnostics, and information technologies, Siemens' innovations help physicians detect, diagnose and treat breast cancer in its earliest, most treatable stages, as well as providing them with comprehensive after-care solutions. This holistic approach enables shorter exams, streamlined workflow, and improved patient outcomes. With clinical guidelines suggesting different types of exams for breast care, imaging technologies are playing an increasing role in all stages of breast care. At RSNA, Siemens is showcasing its latest advancements in breast ultrasound and magnetic resonance imaging (MRI), as well as the next-generation of digital mammography systems.

MAGNETOM Espree - Pink

The American Cancer Society's new screening guidelines recommend that high-risk women receive an annual MRI, which could impact up to 1.4 million women.(1)

Siemens' latest innovation in MRI, the MAGNETOM(R) Espree - Pink, is a dedicated MR breast scanner which combines the Open Bore design of the MAGNETOM Espree with the Sentinelle Vanguard for Siemens, a breast coil solution that offers exceptional breast imaging and biopsy access. MAGNETOM Espree - Pink offers unmatched patient comfort, unique applications, and an innovative workflow pushing MRI Breast Care to the next level.

The MAGNETOM Espree - Pink offers the same unprecedented level of patient comfort of the MAGNETOM Espree, the worlds first Open Bore MRI. Enabling feet-first and head-first positioning and excellent access to perform biopsies, the system has unparalleled openness with a 70 cm Open Bore and the shortest system on the market (125 cm) for increased comfort.

This MR system provides a comprehensive portfolio of routine and advanced applications for breast care, including syngo VIEWS for routine imaging, syngo GRACE for spectroscopy, and syngo BLADE for motion-fre
'/>"/>

SOURCE Siemens Healthcare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Siemens Extends Tender Offer for Acquisition of Dade Behring
2. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
3. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
4. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
5. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
6. Siemens Building Technologies Pioneers Wireless Solution for St. Anthonys Sensitive Environment
7. Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. VIDEO from Medialink and Siemens: Worlds Smallest Ultrasound Package Launches in the U.S.
10. Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007
11. James Cracknell Launches Siemens Stroke for Stroke Week
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Nonprofit Goes RVing to Promote Pet and Human Health 48962 1Nonprofit Goes RVing to Promote Pet and Human Health 48962 2Nonprofit Goes RVing to Promote Pet and Human Health 48962 3HPV Vaccine Acceptability Study Announces Results 48959 1HPV Vaccine Acceptability Study Announces Results 48959 2HPV Vaccine Acceptability Study Announces Results 48959 3Heart Association Warns of Surgery Risks in Obese 48956 1Heart Association Warns of Surgery Risks in Obese 48956 2